Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Signs and Symptoms The C-peptide as a risk factor of development of type 1 diabetes in the first degree relatives of the autoimmunological diabetic patients

The C-peptide as a risk factor of development of type 1 diabetes in the first degree relatives of the autoimmunological diabetic patients

Endokrynol Pol. 2009 Sep-Oct;60(5):357-62.

[Article in Polish]

Siewko K, Szelachowska M, Popławska-Kita A, Szpak P, Nikołajuk A, Górska M.

Klinika Endokrynologii, Diabetologii i Chorób Wewnetrznych Uniwersytetu Medycznego, Białystok. This e-mail address is being protected from spambots. You need JavaScript enabled to view it

INTRODUCTION: People with a high risk of development of type 1 diabetes, like first degree relatives, have characteristics for diabetes immunological/ or metabolic/or genetic markers. Presence of these markers in the blood increase the risk of development of clinically symptoms of the disease. The aim of the study was to evaluate the fasting level of the C-peptide, depending on immunological markers presence (anti-GAD, IAA and anti-IA2 antibodies) and usefulness of this parameter in the risk assessment of development of type 1 diabetes in the first degree relatives of autoimmunological diabetic patients. MATERIAL AND METHODS: The study was carried out in the group of 90 relatives in age from 13 to 65 (an average of age 33.1 +/- 15.48 years old) and an average BMI 24.6 +/- 4.95 kg/m(2) (17-38 kg/m(2)). The fasting level of C-peptide was marked by ELISA method, anti-GAD, IAA, anti-IA2 antibodies titres by RIA method. RESULTS: Lowered level of the C-peptide secretion was not observed in our study. In 22 persons (24.44%) increased of the fasting C-peptide secretion was assessed (> 2.9 ng/ml). Within this group, 7 relatives (31.8%) was positive titre of at least one of antibodies. We observed the positive correlation between C-peptide secretion and IAA (r = 0.282; p < 0.002). Until present moment no clinical symptoms of diabetes were observed in none of the persons. CONCLUSIONS: The increase of fasting level of C-peptide can indicate compensatory increase of beta cell secretion. It can indirectly prove the presence of insulin resistance in this group of people. The presence of higher level of C-peptide and positive IAA titre with no clinical symptoms of type 1 diabetes, seems to be the prognostic factor to retard of clinical symptoms of diabetes.

PMID: 19885806

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 7 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here